S&P 500   2,968.34 (-0.06%)
DOW   26,829.06 (+0.05%)
QQQ   191.29 (+0.09%)
AAPL   237.63 (+0.60%)
FB   183.83 (-0.20%)
MSFT   139.93 (+0.18%)
AMZN   1,726.75 (-0.30%)
NVDA   185.67 (-0.17%)
MU   45.04 (-0.16%)
BABA   171.59 (-0.78%)
GE   8.74 (-0.80%)
TSLA   255.45 (+3.05%)
AMD   29.82 (+0.24%)
T   37.43 (-0.43%)
F   8.82 (+0.46%)
ACB   3.49 (-5.43%)
PRI   121.40 (-0.24%)
NFLX   283.10 (+0.06%)
BAC   29.10 (+0.66%)
GILD   64.79 (+1.25%)
DIS   129.87 (-0.12%)
S&P 500   2,968.34 (-0.06%)
DOW   26,829.06 (+0.05%)
QQQ   191.29 (+0.09%)
AAPL   237.63 (+0.60%)
FB   183.83 (-0.20%)
MSFT   139.93 (+0.18%)
AMZN   1,726.75 (-0.30%)
NVDA   185.67 (-0.17%)
MU   45.04 (-0.16%)
BABA   171.59 (-0.78%)
GE   8.74 (-0.80%)
TSLA   255.45 (+3.05%)
AMD   29.82 (+0.24%)
T   37.43 (-0.43%)
F   8.82 (+0.46%)
ACB   3.49 (-5.43%)
PRI   121.40 (-0.24%)
NFLX   283.10 (+0.06%)
BAC   29.10 (+0.66%)
GILD   64.79 (+1.25%)
DIS   129.87 (-0.12%)
Log in

Alexion Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ALXN)

$101.52
+2.27 (+2.29 %)
(As of 10/14/2019 11:24 AM ET)
Today's Range
$98.73
Now: $101.52
$101.71
50-Day Range
$95.42
MA: $103.91
$123.98
52-Week Range
$92.56
Now: $101.52
$141.86
Volume528,375 shs
Average Volume1.84 million shs
Market Capitalization$22.76 billion
P/E Ratio14.32
Dividend YieldN/A
Beta1.67
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.13 billion
Cash Flow$9.33 per share
Book Value$41.08 per share

Profitability

Net Income$77.60 million

Miscellaneous

Employees2,656
Market Cap$22.76 billion
Next Earnings Date10/23/2019 (Confirmed)
OptionableOptionable

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.


Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its earnings results on Wednesday, July, 24th. The biopharmaceutical company reported $2.64 EPS for the quarter, topping the Zacks' consensus estimate of $2.13 by $0.51. The biopharmaceutical company had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.18 billion. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. The company's quarterly revenue was up 15.1% compared to the same quarter last year. During the same period last year, the company posted $2.07 earnings per share. View Alexion Pharmaceuticals' Earnings History.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, October 23rd 2019. View Earnings Estimates for Alexion Pharmaceuticals.

How can I listen to Alexion Pharmaceuticals' earnings call?

Alexion Pharmaceuticals will be holding an earnings conference call on Wednesday, October 23rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals updated its FY 2019 earnings guidance on Wednesday, July, 24th. The company provided EPS guidance of $9.65-9.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.44. The company issued revenue guidance of $4.75-4.8 billion, compared to the consensus revenue estimate of $4.78 billion.

What price target have analysts set for ALXN?

17 analysts have issued 12 month price targets for Alexion Pharmaceuticals' shares. Their predictions range from $135.00 to $186.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $160.56 in the next year. This suggests a possible upside of 59.9% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.

What is the consensus analysts' recommendation for Alexion Pharmaceuticals?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.

Has Alexion Pharmaceuticals been receiving favorable news coverage?

News coverage about ALXN stock has trended negative on Monday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Alexion Pharmaceuticals.

Who are some of Alexion Pharmaceuticals' key competitors?

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Celgene (CELG), Alibaba Group (BABA), Gilead Sciences (GILD), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA), Visa (V), Biogen (BIIB), Allergan (AGN) and Amgen (AMGN).

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the folowing people:
  • Dr. Ludwig N. Hantson, CEO & Director (Age 56)
  • Mr. Paul J. Clancy, Exec. VP & CFO (Age 57)
  • Ms. Anne-Marie Law, Exec. VP and Chief Patient & Employee Experience Officer (Age 52)
  • Mr. Brian M. Goff, Exec. VP & Chief Commercial Officer (Age 50)
  • Dr. John J. Orloff, Exec. VP and Head of R&D (Age 62)

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.03%), Gulf International Bank UK Ltd (0.02%), Pacer Advisors Inc. (0.02%), Private Trust Co. NA (0.01%), Crossmark Global Holdings Inc. (0.01%) and Altman Advisors Inc. (0.01%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Christopher J Coughlin, Daniel Bazarko, Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.

Which major investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Gulf International Bank UK Ltd, Advantage Investment Management LLC, Landsberg Bennett & Dubbaneh LLC and Juncture Wealth Strategies LLC. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

Which major investors are buying Alexion Pharmaceuticals stock?

ALXN stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Polianta Ltd, Fulton Bank N.A., XR Securities LLC, Pacer Advisors Inc., Private Trust Co. NA, Altman Advisors Inc. and Gradient Investments LLC. View Insider Buying and Selling for Alexion Pharmaceuticals.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $100.40.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $22.51 billion and generates $4.13 billion in revenue each year. The biopharmaceutical company earns $77.60 million in net income (profit) each year or $7.09 on an earnings per share basis. Alexion Pharmaceuticals employs 2,656 workers across the globe.View Additional Information About Alexion Pharmaceuticals.

What is Alexion Pharmaceuticals' official website?

The official website for Alexion Pharmaceuticals is http://www.alexion.com/.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]


MarketBeat Community Rating for Alexion Pharmaceuticals (NASDAQ ALXN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,145 (Vote Outperform)
Underperform Votes:  652 (Vote Underperform)
Total Votes:  1,797
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Featured Article: What is Depreciation?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel